Lung Cancer Awareness Month (see related measures) | National Quality Measures Clearinghouse

Search | National Quality Measures Clearinghouse

Health Awareness Topics: November 2017

• Lung Cancer Awareness Month (see related measures)

1-20 of 51 results for

“Neoplasms”

• MEASURE SUMMARY
 
• NQMC:010950
 
• 2014 DEC

Diagnostic flexible bronchoscopy: proportion of patients diagnosed with malignancy where sufficient tissue was obtained for genetic profiling/all tissue sent for profiling.

British Thoracic Society

Compare

• MEASURE SUMMARY
 
• NQMC:011231
 
• 2017 FEB

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:011234
 
• 2017 FEB

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) undergoing resection by lobectomy or pneumonectomy who have at least 1 node from at least 3 N2 stations sampled at time of resection or at previous mediastinoscopy.

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:010971
 
• 2016 DEC
• NQF-ENDORSED MEASURE

Thoracic surgery: percentage of patients aged 18 years and older undergoing elective lung resection for lung cancer who developed any of the specified postoperative complications.

Society of Thoracic Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:011228
 
• 2017 FEB

Lung cancer: proportion of patients with lung cancer who have a pathological diagnosis (including following surgical resection).

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:010216
 
• 2016 JAN

Optimizing patient exposure to ionizing radiation: percentage of final reports for CT imaging studies of the thorax for patients aged 18 years and older with documented follow-up recommendations for incidentally detected pulmonary nodules based at a minimum on nodule size and patient risk factors.

American College of Radiology; Physician Consortium for Performance Improvement®

Compare

• MEASURE SUMMARY
 
• NQMC:010988
 
• 2016 DEC

Lung cancer: percentage of non-surgical biopsies in patients with clinical stage IV non-squamous non-small cell lung cancer that obtained an adequate amount of tissue for molecular testing.

American College of Chest Physicians

Compare

• MEASURE SUMMARY
 
• NQMC:010956
 
• 2014 DEC

Diagnostic flexible bronchoscopy: proportion of patients with non small cell lung cancer diagnosis confirmed from endobronchial ultrasound (EBUS) sampling with non small cell lung cancer, not otherwise specified (NSCLC NOS) diagnosed from EBUS sampling.

British Thoracic Society

Compare

• MEASURE SUMMARY
 
• NQMC:011237
 
• 2017 FEB

Lung cancer: proportion of patients with limited stage (stage I to IIIB) small cell lung cancer (SCLC), performance status 0 or 1, who receive chemoradiotherapy (radiotherapy greater than or equal to 40Gy and concurrent or sequential platinum-based chemotherapy).

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:010994
 
• 2016 DEC

Lung cancer: percentage of patients with lung cancer in whom a performance status measure is documented prior to treatment.

American College of Chest Physicians

Compare

• MEASURE SUMMARY
 
• NQMC:006147
 
• 2010 APR

Cancer - dyspnea: percentage of patients who reported new or worsening dyspnea for whom there was documentation of cause or of investigation of at least one of the following: hypoxia, anemia, bronchospasm or chronic obstructive pulmonary disease, pleural effusion, tumor obstruction of bronchi or the trachea, pneumonia, or pulmonary embolism.

RAND Corporation

Compare

• MEASURE SUMMARY
 
• NQMC:011240
 
• 2017 FEB

Lung cancer: proportion of patients with small cell lung cancer (SCLC) who receive chemotherapy ± radiotherapy.

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:010991
 
• 2016 DEC

Lung cancer: percentage of patients with clinical stage IB or higher, but no evidence of metastatic disease, who have had a mediastinal lymph node sampling procedure performed prior to the initiation of curative intent therapy.

American College of Chest Physicians

Compare

• MEASURE SUMMARY
 
• NQMC:011243
 
• 2017 FEB

Lung cancer: proportion of patients with lung cancer who receive treatment with curative intent (surgery, radical radiotherapy or chemoradiotherapy) who die within 90 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:006150
 
• 2010 APR

Cancer - dyspnea: percentage of patients in the hospital treated for dyspnea who had an assessment within 24 hours that the treatment was effective in relieving dyspnea or that a change in treatment for dyspnea was made.

RAND Corporation

Compare

• MEASURE SUMMARY
 
• NQMC:010244
 
• 2015 MAR

Diagnostic imaging: percentage of screenings for lung cancer interpreted as positive (Lung-RADS Category 3 or 4).

American College of Radiology

Compare

• MEASURE SUMMARY
 
• NQMC:010942
 
• 2014 DEC

Diagnostic flexible bronchoscopy: proportion of adults with suspected lung cancer or requiring an urgent bronchoscopy having bronchoscopy within 7 working days of the decision to perform bronchoscopy.

British Thoracic Society

Compare

• MEASURE SUMMARY
 
• NQMC:011246
 
• 2017 FEB

Lung cancer: proportion of patients with N2 disease who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo contrast enhanced CT or contrast enhanced MRI prior to start of treatment.

NHS Scotland; Scottish Cancer Taskforce

Compare

• MEASURE SUMMARY
 
• NQMC:010969
 
• 2016 DEC

Thoracic surgery: percentage of patients aged 18 years and older undergoing elective lobectomy for lung cancer who had a prolonged length of stay greater than 14 days.

Society of Thoracic Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:010972
 
• 2016 DEC
• NQF-ENDORSED MEASURE

Thoracic surgery: percentage of patients aged 18 years and older undergoing resection for lung or esophageal cancer who had clinical staging provided prior to surgery.

Society of Thoracic Surgeons